Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-aminopyridine vs Atenolol in Vestibular Migraine
NCT03578354Phase 2Withdrawn
- Sponsor
- Massachusetts Eye and Ear
- Start
- Jan 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dalfampridine in vestibular migraine (VM) (3 arms), sponsored by Massachusetts Eye and Ear. Primary endpoint: Change in Dizziness Handicap Score at 14 weeks. Planned start Jan 2019; status: withdrawn.
02
Drugs
dalfampridine
03
Conditions
vestibular migraine (VM)
Beyond the preview
Go deeper on NCT03578354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03578354.